Free Trial
→ Trump’s Plan May Undo 1933’s Biggest Financial Injustice (From American Hartford Gold) (Ad)tc pixel

Carl Byrnes Analyst Performance

Analyst at Northland Securities

Carl Byrnes is a stock analyst at Northland Securities in the medical sector, covering 16 publicly traded companies. Over the past year, Carl Byrnes has issued 2 stock ratings, including and buy recommendations. While full access to Carl Byrnes' proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Carl Byrnes' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Analyst Rating
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
72 Last 9 Years
Buy Recommendations
91.43% 64 Buy Ratings
Companies Covered
16 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy91.4%64 ratings
Hold8.6%6 ratings
Sell0.0%0 ratings

Out of 70 total stock ratings issued by Carl Byrnes at Northland Securities, the majority (91.4%) have been Buy recommendations, followed by 8.6% Hold.

Best & Worst Calls

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
16 companies

Carl Byrnes, an analyst at Northland Securities, currently covers 16 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
16 companies		100.0%

Carl Byrnes of Northland Securities specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
PHARMACEUTICAL PREPARATIONS
7 companies		43.8%
MED PRODUCTS
3 companies		18.8%
MED - DRUGS
2 companies		12.5%
MED - BIOMED/GENE
2 companies		12.5%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
1 company		6.3%
MED-BIOMED/GENE
1 company		6.3%

Carl Byrnes' Ratings History at Northland Securities

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
Export to Excel
CompanyReport DateActionReport Date Price12-Month
Price Target		Rating12-Month
Price & ROI		Details
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
9/3/2025Initiated Coverage$39.75$55.00Outperform
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
8/14/2025Boost Price Target$12.87$19.00Outperform
Today's Ratings
Top-Rated Stocks
More Ratings Tools